Influence of short-chain cell-penetrating peptides on transport of doxorubicin encapsulating receptor-targeted liposomes across brain endothelial barrier

Pharmaceutical Research

Volumn 31, Issue 5, 2014, Pages 1194-1209

  Sharma, Gitanjali ^a   Modgil, Amit ^a   Zhong, Tiecheng ^a   Sun, Chengwen ^a   Singh, Jagdish ^a,b  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

blood brain barrier; cell penetrating peptides; dual functionalized; liposomes; tumor

Indexed keywords

CELL PENETRATING PEPTIDE; DOXORUBICIN; LIPOSOME; MASTOPARAN; PENETRATIN; TRANSFERRIN; ANTINEOPLASTIC ANTIBIOTIC; BIOMATERIAL; DRUG RECEPTOR; PEPTIDE;

ARTICLE; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CYTOTOXICITY ASSAY; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG TRANSPORT; DRUG TUMOR LEVEL; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; BRAIN; CYTOLOGY; HEMOLYSIS; METABOLISM; VASCULAR ENDOTHELIUM;

ANTIBIOTICS, ANTINEOPLASTIC; BIOCOMPATIBLE MATERIALS; BRAIN; BRAIN NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; ENDOTHELIUM, VASCULAR; HEMOLYSIS; LIPOSOMES; PEPTIDES; RECEPTORS, DRUG;

EID: 84902271583     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1242-x     Document Type: Article

References (56)

1. Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med. 2012;18:385-93.
2. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 2005;57:637-51.
3. Rooy IV, Mastrobattista E, Storm G, Hennink WE, Schiffelers RM. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release. 2011;150:30-6.
4. Emerich DF, Snodgrass P, Pink M, Bloom F, Bartus RT. Central analgesic actions of loperamide following transient permeation of the blood-brain barrier with Cereport (RMP-7). Brain Res. 1998;801:259-66.
5. Scherrmann JM. Drug delivery to brain via the blood-brain barrier. Vasc Pharmacol. 2002;38:349-54.
6. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A. 1996;93:14164-9.
7. Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier insulin receptor. J Neurochem. 1985;44:1771-8.
8. Oba M, Fukushima S, Kanayama N, Aoyagi K, Nishiyama N, Koyama H, et al. Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins. Bioconjug Chem. 2007;18:1415-23.
9. Sharma G, Modgil A, Layek B, Arora K, Sun C, Law B, et al. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection. J Control Release. 2013;167:1-10.
10. Zhong MQ, Hongyan L, Hongzhe U, Kwokping H. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev. 2002;54:561-87.
11. Cheng Y, Zak O, Alsen P, Harrison SC, Watz T. Structure of the human transferrin receptor-transferrin complex. Cell. 2004;116:565-76.
12. Sharma G, Modgil A, Sun C, Singh J. Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection efficiency and transport across blood-brain barrier model. J Pharm Sci. 2012;101:2468-78.
13. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. Dual ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release. 2011;153:141-8.
14. Varga CM, Wickham TJ, Lauffenburger DA. Receptor mediated targeting of gene delivery vectors: insights from molecular mechanisms for improved vehicle design. Biotechnol Bioeng. 2000;70:593-605.
15. Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta. 1816;2011:232-46.
16. Mae M, Myrberg H, EI-Andaloussi S, Langel U. Design of a tumor homing cell penetrating peptide for drug delivery. Int J Pept Res Ther. 2009;15:11-5.
17. Ziegler A, Nervi P, Durrenberger M, Seelig J. The cationic cell-penetrating peptide CPP TAT derived from the HIV-1 protein Tat is rapidly transported into living fibroblasts: optical, biophysical and metabolic evidence. Biochemistry. 2005;44:138-48.
18. Meng W, Kallinteri P, Walker DA, Parker TL, Garnett MC. Evaluation of poly (Glycerol-Adipate) nanoparticle uptake in an in vitro 3-D brain tumor co-culture model. Exp Biol Med. 2007;232:1100-8.
19. Murray S, Rooprai H, Selway R, Pilkington G. A novel three-dimensional "all human" in vitro brain tumor invasion model. Neuro-Oncology. 2005;7:307-8.
20. Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13(6):1663-74.
21. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol. 2000;18:410-4.
22. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. 1998;8:84-7.
23. Pooga M, But C, Kihlmark M, Hallbrink M, Fernaeus S, Raid R, et al. Cellular translocation of proteins by transportan. J FASEB. 2001;15:1451-3.
24. Rousselle C, Smirnova M, Clair P, Lefauconnier JM, Chavanieu A, Calas B, et al. Enhanced delivery of doxorubicin into the brain via a peptide- vector-mediated strategy: saturation kinetics and specificity. JPET. 2001;296:124-31.
25. Rea JC, Barron AE, Shea LD. Peptide-mediated lipofection is governed by lipoplex physical properties and the density of surface-displayed amines. J Pharm Sci. 2008;97:4794-806.
26. Miedel MC, Hulmes JD, Pan YEC. The use of fluorescamine as a detection reagent in protein microcharacterization. J Biochem Biophys Methods. 1989;18:37-52.
27. Yub E, Kojima C, Sakaguchi N, Harada A, Koiwai K, Kono K. Gene delivery to dendritic cells mediated by complexes of lipoplexes and pH-sensitive fusogenic polymer-modified liposomes. J Control Release. 2008;130:77-83.
28. Yamano S, Dai J, Yuvienco C, Khapli S, Moursi AM, Montclare JK. Modified Tat peptide with cationic lipids enhances gene transfection efficiency via temperature-dependent and caveolae-mediated endocytosis. J Control Release. 2011;152:278-85.
29. Rejman J, Bragonzi A, Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol Ther. 2005;12:468-74.
30. Vercauteren D, Vandenbroucke RE, Jones AT, Rejman J, Demeester J, De Smedt SC, et al. The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls. Mol Ther. 2010;18:561-9.
31. Nam HY, Kwon SM, Chung H, Lee SY, Kwon SH, Jeon H, et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2009;135:259-67.
32. Gaillard PJ, Voorwinden HV, Nielsen JL, Ivanov A, Atsumi R, Engman H, et al. Establishment and functional characterization of an in vitro model of the blood-brain barrier comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci. 2001;12:215-22.
33. Fenke H, Galla HJ, Beuckmann CT. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res Brain Res Protoc. 2000;5:248-56.
34. Erben M, Decker S, Franke H, Galla HJ. Electrical resistance measurements on cerebral capillary endothelial cells - a new technique to study small surface areas. J Biochem Biophys Methods. 1995;30:227-38.
35. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. In-vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 2003;24:1121-31.
36. Lee D, Powers K, Baney R. Physicochemical properties and blood compatibility of acylated chitosan nanoparticles. Carbohydr Polym. 2004;58:371-7.
37. Rodal SK, Skretting G, Garred O, Vilhardt F, Deurs BV, Sandvig K. Extraction of cholesterol with Methyl-b-Cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol Biol Cell. 1999;10:961-74.
38. Audouy SAL, de Leiji LFMH, Hoekstra D, Molema G. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res. 2002;19:1599-605.
39. Jones SW, Christison R, Bundell K, Voyce CJ, Brockbank SMV, Newham P, et al. Characterization of cell-penetrating peptide-mediated peptide delivery. Br J Pharmacol. 2005;145:1093-102.
40. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta. 2001;1513:207-16.
41. Moreira JN, Ishida T, Gaspar R, Allen TM. Use of the post-insertion technique to insert peptide ligands into preformed stealth liposomes with retention of binding activity and cytotoxicity. Pharm Res. 2002;19:265-9.
42. Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2012;64:640-65.
43. Roney CC, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release. 2005;108:193-214.
44. Krex D, Klink B, Hartmann C, Deimling AV, Pietsch T, Simon M, et al. German Glioma Network, long-term survival with glioblastoma multiforme. Brain. 2007;130:2596-606.
45. McNeil DE, Cote TR, Clegg L, Rorke BL. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update: surveillance epidemiology and end results. Med Pediatr Oncol. 2002;39:190-4.
46. Saar K, Lindgren M, Hansen M, Eiriksdottir E, Jiang Y, Rosenthal-Aizman K, et al. Cell-penetrating peptides: a comparative membrane toxicity study. Anal Biochem. 2005;345:55-65.
47. Kim JB. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol. 2005;15:365-77.
48. Sourla A, Doillon C, Koutsilieris M. Three-dimensional type I collagen gel system containing MG-63 osteoblasts-like cells as model for studying local bone reaction caused by metastatic cancer cells. Anticancer Res. 1996;16:2773-80.
49. Bell E. Strategy for the selection of scaffolds for tissue engineering. Tissue Eng. 1995;1:163-79.
50. Provenzale JM, Mukundan S, Dewhirst M. The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. Am J Roentgenol. 2005;185:763-7.
51. Ishihara H, Kubota H, Lindberg RL, Leppert D, Gloor SM, Errede M, et al. Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins. J Neuropathol Exp Neurol. 2008;67:435-48.
52. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature. 1987;325:253-7.
53. Antohi S, Brumfeld V. Polycation-cell surface interactions and plasma membrane compartments in mammals. Interference of oligocation with polycationic condensation. Z Naturforsch C. 1984;39:767-75.
54. Cardozo AK, Buchillier V, Mathieu M, Chen J, Ortis F, Ladrire L, et al. Cell-permeable peptides induce dose- and length-dependent cytotoxic effects. Biochim Biophys Acta Biomembr. 2007;1768:2222-34.
55. Deaglio S, Capobianco A, Cali A, Bellora F, Alberti F, Righi L, et al. Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum. Blood. 2002;100:3782-9.
56. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature. 1984;312:162-3.